These findings are similar to those from a previous trial in patients with PSC without cirrhosis who were treated with 100 mg cilofexor QD (13) and in a study with healthy volunteers treated with 10, 30, 100, or 300 mg cilofexor QD (21), in which rapid, dose-dependent increases in FGF19 levels after administration of cilofexor were observed. Here, FGF19 is linked to pancreatic serous cystadenoma.